CapsoVision (CV) Stock Price, News & Analysis

Company Overview

CapsoVision, Inc. (NASDAQ: CV) is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out.

In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting. This platform integrates seamlessly with the CapsoCam capsule, allowing physicians to access endoscopy images and diagnostic reports remotely and collaborate more efficiently on case reviews. The combination of the CapsoCam Plus capsule and the CapsoCloud platform supports a patient-centric workflow and can help reduce turnaround times for gastroenterology practices.

Founded on principles of innovation in gastrointestinal imaging, CapsoVision operates from its headquarters in Rochester, Minnesota, and serves a broad customer base across the United States and select international markets through a network of direct sales representatives and distribution partners. Its products have obtained regulatory clearances in multiple regions, and the company continues to invest in clinical research and new product development aimed at enhancing patient comfort and diagnostic accuracy.

CapsoVision is led by a management team with deep expertise in medical device commercialization and gastroenterology products. Under their guidance, the company focuses on expanding its market presence, advancing regulatory approvals, and fostering strategic collaborations with healthcare providers to support adoption of capsule endoscopy as a minimally invasive alternative to traditional endoscopic procedures.

Key Stats

• Today's Range: $6.67 to $7.00
• 50-Day Range: $5.40 to $8.69
• 52-Week Range: $3.43 to $15.37
• Volume: 80,441 shs
• Average Volume: 87,277 shs
• Market Capitalization: $344.75 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.50
• Consensus Rating: Moderate Buy

CapsoVision Stock Analysis - MarketRank™

CapsoVision scored higher than 36% of companies evaluated by MarketBeat, and ranked 57th out of 86 stocks in the manufacturing sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

CapsoVision has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

CapsoVision has a consensus price target of $8.50, representing about 23.2% upside from its current price of $6.90.

Amount of Analyst Coverage

CapsoVision has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of CapsoVision is -2.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CapsoVision is -2.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

CapsoVision has a P/B Ratio of 24.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.89% of the float of CapsoVision has been sold short.

Short Interest Ratio / Days to Cover

CapsoVision has a short interest ratio ("days to cover") of 13.93, which indicates bearish sentiment.

Change versus previous month

Short interest in CapsoVision has recently decreased by 0.96%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CapsoVision does not currently pay a dividend.

Dividend Growth

CapsoVision does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: N/A

News Sentiment

CapsoVision has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.00 average news sentiment score of Manufacturing companies.

News Coverage This Week

MarketBeat has tracked 1 news article for CapsoVision this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for CV on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CapsoVision insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.30% of the stock of CapsoVision is held by insiders.

Percentage Held by Institutions

CapsoVision has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 6/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Surgical, Medical, And Dental Instruments And Supplies
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:CV
• CIK: 1378325
• Web: N/A
• Phone: (408) 370-4790
• Fax: N/A
• Employees: 90
• Year Founded: 2005

Price Target and Rating

• Average Price Target for CapsoVision: $8.50
• High Price Target: $10.00
• Low Price Target: $7.00
• Potential Upside/Downside: +23.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$25.32 million
• Net Margins: -198.87%
• Pretax Margin: -198.70%
• Return on Equity: N/A
• Return on Assets: -136.03%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.57
• Quick Ratio: 3.92

Sales & Book Value

• Annual Sales: $13.56 million
• Price / Sales: 25.42
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.28 per share
• Price / Book: 24.64

Miscellaneous

• Outstanding Shares: 49,964,000
• Free Float: 48,815,000
• Market Cap: $344.75 million
• Optionable: N/A
• Beta: N/A